Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index; 15 of the 54 sources its claims cite were checked for support.
Abstract
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF. Here, in this randomized, double-blind, placebo-controlled trial, participants (n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg dose) or placebo. The mean relative change from baseline in LF at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% (placebo) (all P < 0.001 versus placebo). At 24 weeks, normal LF (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg) and 0% (placebo) of participants. LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism. The ClinicalTrials.gov registration is NCT04881760 .
Overview
CoChat Summary
## TL;DR
This randomized phase 2a substudy found that once-weekly retatrutide substantially reduced liver fat in participants with MASLD over 24 weeks, with the largest effects at 8 mg and 12 mg. The paper reports that more than 85% of participants in the two highest-dose groups achieved liver fat <5% by 24 and 48 weeks.
## Key findings
- In 98 randomized participants with MASLD and liver fat ≥10% by MRI-PDFF, mean relative liver fat change at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), versus +0.3% with placebo; all were P < 0.001 versus placebo.
- At 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), and 86% (12 mg), versus 0% with placebo.
- At 48 weeks, relative liver fat change remained large: −51.3%, −59.0%, −81.7%, and −86.0% for 1, 4, 8, and 12 mg, versus −4.6% with placebo; all doses were superior to placebo (P < 0.001).
- Retatrutide also reduced body weight and abdominal fat: at 48 weeks, body weight changed by −8.6%, −16.3%, −23.8%, and −25.9% across the 1, 4, 8, and 12 mg doses, and VAT/ASAT were significantly reduced versus placebo.
## Methods
- Randomized, double-blind, placebo-controlled phase 2a substudy of a 48-week multicenter obesity trial; participants received once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo.
- The MASLD substudy included 98 participants from the parent trial who had MASLD and liver fat content ≥10% by MRI-PDFF; the main study randomized 338 participants total.
- Primary outcome was relative liver fat change at 24 weeks by MRI-PDFF; secondary/exploratory outcomes included 48-week liver fat, body weight, waist circumference, VAT/ASAT, metabolic biomarkers, and MASH/fibrosis biomarkers, analyzed with mixed models for repeated measures and logistic regression.
## Limitations
- The paper states the substudy had a relatively small sample size, was geographically and racially homogeneous (United States only, majority white), excluded patients with type 2 diabetes, lacked liver histology, lacked enrichment for MASH or significant fibrosis, and had no multiplicity control for many statistical tests.
- The paper states that 48-week MRI data were unavailable for 56.1% of participants, limiting interpretation of the 48-week dose-response for liver fat reduction.
- Evident from the text: this was a substudy within an obesity trial, so the MASLD cohort may not represent broader MASLD populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






![Extended Data Fig. 3 Percent of participants achieving liver fat reduction targets at week 48. Results shown as LS means ± SE. Comparisons vs. PBO were done by using 2-sided z-tests without multiplicity adjustment. Fewer participants had MRIs at Week 48 (n=8 [PBO], n=9 [1 mg RETA], n=9 [4 mg RETA], n=8 [8 mg RETA], n=9 [12 mg RETA]) compared with Week 24 (n=14 [PBO], n=16 [1 mg RETA], n=15 [4 mg RETA], n=17 [8 mg RETA], n=15 [12 mg RETA]). MRI, magnetic resonance imaging; PBO, placebo; RETA, retatrutide.](https://figures.cochat.ai/paper-figures/baf0e36e207846f3ba74e25119848651/triple-hormone-receptor-agonist-retatrutide-for-metabolic-dysfunction-associated-figure-7.jpg)




![Extended Data Fig. 8 Evaluation of drug-induced serious hepatotoxicity (eDISH) plots. a, eDISH plot for MASLD substudy population (n=98). b, eDISH plot for overall obesity population (n=336). eDISH, evaluation of Drug-Induced Serious Hepatotoxicity; RETA, retatrutide; ULN, upper limit of normal. Notes on interpretation of the eDISH plot48. ● Hy’s Law refers to the increased risk of serious drug-induced liver injury that is present when both aminotransferase elevations (>3 times the upper limit of the normal range [ULN]) and total bilirubin elevations (>2 times the ULN) occur together. This is denoted by the upper right quadrant of the eDISH plot. ● Temple’s corollary refers to the observation that drugs which caused a marked preponderance of lesser liver injuries compared with control agents, shown by more frequent serum aminotransferase elevations, were more likely to show more Hy’s Law cases. This is denoted by the lower right quadrant of the eDISH plot. ● The upper left quadrant refers to the cholestasis range. ● The lower left quadrant includes values within or near the reference range.](https://figures.cochat.ai/paper-figures/27230ff133c549c59402700f32a2c98f/triple-hormone-receptor-agonist-retatrutide-for-metabolic-dysfunction-associated-figure-12.jpg)
Verification
Claims the paper makes
13 Valid · 2 Not valid · 21 Not checked · 116 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, liver fat was normalized (to <5% liver fat) in 32 (64%) of 50 participants after a mean of 22.5 weeks20.”
§ Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial > Discussion
What the sources say
- Supportedcites [20] Pooler, B. D. et al. Monitoring fatty liver disease with MRI following bariatric surgery: a prospective, dual-center study. Radiology 290, 682–690 (2019). source
The Results report that liver fat normalized to a PDFF below 5% in 32 of 50 participants (64%). The same passage gives a mean estimated time to normalization of 22.5 weeks. (LLM, conf=0.95)
plainn = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For weight loss categories of ≤5%, >5% to ≤10%, and >10%, liver fat reduction with efinopegdutide (52.4%, 76.6% and 86.2%, respectively) was greater than with semaglutide (13.4%, 39.6% and 64.2%, respectively)14.”
§ Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial > Discussion
What the sources say
- Supportedcites [14] Romero-Gómez, M. et al. A phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease. J. Hepatol. 79, 888–897 (2023). sourceExperimental — accuracy not yet measured
The Week 24 results (passage [1]; page not provided) report the same liver-fat reductions for all three weight-loss categories in both treatment groups. The figure caption (passage [7]) identifies these as reductions in liver fat content by weight-loss category. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This finding is consistent with a ‘floor effect’ for hepatic fat, which is unlikely to be reduced below the median of 2.1% observed in the large UK Biobank study27.”
§ Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial > Discussion
What the sources say
- Partly supportedcites [27] Wilman, H. R. et al. Characterisation of liver fat in the UK Biobank cohort. PLoS ONE 12, e0172921 (2017). sourceExperimental — accuracy not yet measured
The Results report a median hepatic fat fraction of 2.11% in the UK Biobank cohort, supporting the cited figure. They do not establish a floor effect or that hepatic fat is unlikely to be reduced below 2.1%; Table 4 reports values below that level, including a median of 1.32% in the lower-BMI, non-diabetic subset. (LLM, conf=0.89)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a recent 24-week study, the dual GLP-1/GCG agonist, efinopegdutide, demonstrated greater liver fat lowering efficacy than semaglutide for the same degree of weight loss.”
§ Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial > Discussion
What the sources say
- Supportedcites [14] Romero-Gómez, M. et al. A phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease. J. Hepatol. 79, 888–897 (2023). source
The Discussion reports a significantly larger reduction in liver fat content with efinopegdutide than with semaglutide despite similar reductions in body weight. The Week 24 results also show greater liver-fat reductions with efinopegdutide within each weight-loss category. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with progressive adipose tissue reductions and improvements in insulin sensitivity30.”
§ Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial > Discussion
What the sources say
- Supportedcites [30] Ye, R. & Scherer, P. E. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2, 133–141 (2013). source
The Introduction (page not provided) reports that adiponectin is reduced in obesity and that higher adiponectin is positively associated with insulin sensitivity. It also discusses a study in which reduced adipose tissue mass could partly mediate the relationship between increased adiponectin and insulin sensitivity. These passages support the citing sentence’s cautious description of the changes as consistent with one another. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
76 more claims · 2 with their cited sources checked
Create a free account to see all 152 claims and every source verdict.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 53
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks Up to 25•9% (SEM 2•4) NA Reduction in hepatic fat fraction by <86•0%; no histology available to assess fibrosis Sanyal et al (2024) 140”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [140]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg), and 0% (placebo) of participants.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At 24 weeks, healthy liver fat levels (< 5%) were achieved by 86% of participants on retatrutide 12 mg and 0% in the placebo group.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Phase II trials for tirzepatide and survodutide, a GLP-1/glucagon receptor co-agonist, have also shown positive outcomes in people living with MASH and obesity, demonstrating reduction of inflammation without worsening of fibrosis (4, 69).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glucagon-like peptide-1 receptor agonist (GLP1RA) alone [129] or GLP1RA-based combination agents, including dual (e.g., tirzepatide and survodutide) and triple (e.g., retatrutide) agonists, now demonstrate histological improvements in MASH and fibrosis with weight loss approaching that of bariatric surgery [3,130-133].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [133]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
XGBoost: A Scalable Tree Boosting System
Chen, T., & Guestrin, C. (2016) · Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2939672.2939785 · Cited by 54,569
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 1×
“Nonalcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common chronic liver diseases in the world 1,2 .”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial 6 .”
BackgroundSelf-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“These safety findings are similar to those reported for therapies based on GLP-1 or GIP/GLP-1 agonism for the treatment of type 2 diabetes or obesity 41–45 .”
ResultTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 6×
“Treatment was also associated with improvements in blood pressure (BP), lipids and glycemia 13 .”
BackgroundMethodResultInfluentialSelf-citationThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 1×
“Notably, FGF21 analogs have reduced insulin resistance or decreased liver fat in clinical trials 16,26 ; however, administration of retatrutide at higher doses significantly reduced circulating FGF21 levels, suggesting that retatrutide efficacy in MASLD is unlikely to be attributable to increased…”
BackgroundA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Self-citationGarvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Leptin and the endocrine control of energy balance
Friedman, J. M. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0095-y · Cited by 661 · cited 1×
“The observed reductions in leptin levels with higher doses of retatrutide may reflect a function of this hormone as a circulating indicator of fat stores 29 .”
BackgroundYounossi, Z. M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., & Henry, L. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 576
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522 · cited 1×
“In patients with biopsy-proven MASH, efruxifermin reduced liver fat by up to 72% after 12 weeks and pego-zafermin reduced liver fat by up to 48% after 24 weeks (both FGF21 analogs) 16,17 .”
BackgroundSelf-citationGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Self-citationRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Self-citationHarrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01425-3 · Cited by 368
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · cited 1×
“The GIP/GLP-1 dual agonist, tirzepatide, reduced liver fat and improved biomarkers of MASH and fibrosis in patients with type 2 diabetes (T2D); a phase 2 trial in MASH is ongoing 7,8 .”
BackgroundSelf-citationCoskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316 · cited 3×
“In addition, its glucagon activity may reduce liver fat by stimulating hepatic fatty acid oxidation and reducing hepatic lipogenesis 11,22 .”
BackgroundInfluentialSelf-citationVali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.036 · Cited by 302
Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283 · cited 1×
“Of note, in clinical studies, a relative liver fat reduction of ≥30% has been associated with histological improvement in patients with MASH 21 .”
BackgroundBoland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270
Self-citationAdiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251 · cited 1×
“Adiponectin levels increased in a time-related manner with higher doses of retatrutide, consistent with progressive adipose tissue reductions and improvements in insulin sensitivity 30 .”
BackgroundKuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · cited 1×
“…fat reductions with GLP-1 mono-agonists and the GIP/GLP-1 dual agonist, tirzepatide, were lower than those observed with retatrutide, ranging from 32% after 24 weeks with dulaglutide and 47% after 52 weeks with tirzepatide, to approximately 50% after 72 weeks treatment with semaglutide 8,18,19 .”
BackgroundFibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245 · cited 1×
“Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans 25 .”
BackgroundFlint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16608 · Cited by 224
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
(2013) · Europe PMC (PubMed Central) · Cited by 214
Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.031 · Cited by 206
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202 · cited 2×
“Retatrutide improved fasting lipid profiles including triglycerides, very low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in clinical trials in people with T2D or obesity, while low-density lipoprotein cholesterol was reduced in people with obesity 12,13,28 .”
BackgroundSelf-citationCollagen biology and non‐invasive biomarkers of liver fibrosis
Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International · doi:10.1111/liv.14390 · Cited by 197 · cited 1×
“A potential explanation of the difference in response between the two tests is that pro-C3 may be more indicative of active fibrogenesis, whereas ELF may correlate more with the severity of histological liver fibrosis 36,40 .”
BackgroundGuzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172 · cited 8×
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo 37 .”
BackgroundInfluentialCharacterisation of liver fat in the UK Biobank cohort
Wilman, H. R., Kelly, M., Garratt, S., Matthews, P. M., Milanesi, M., Herlihy, A., Gyngell, M., Neubauer, S., Bell, J. D., Banerjee, R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172921 · Cited by 159
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Senior, J. R. (2014) · Drug Safety · doi:10.1007/s40264-014-0182-7 · Cited by 122
Vuppalanchi, R., Jain, A. K., Deppe, R., Yates, K., Comerford, M., Masuoka, H. C., Neuschwander-Tetri, B. A., Loomba, R., Brunt, E. M., Kleiner, D. E., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.010 · Cited by 116 · cited 1×
“The magnitude of decrease in K-18 observed with retatrutide 8 mg and 12 mg has been associated with greater odds of histological improvement in previous studies of patients with MASH 33 .”
BackgroundLuo, Y., Oseini, A., Gagnon, R., Charles, E. D., Sidik, K., Vincent, R., Collen, R., Idowu, M., Contos, M. J., Mirshahi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30457-y · Cited by 74
Self-citationLee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238717 · Cited by 74 · cited 1×
“A recent meta-analysis proposed K-18 values between 127–191 U l −1 for ruling-out MASH at fixed sensitivity levels and 304–399 U l −1 to rule-in MASH at fixed specificity levels 32 .”
BackgroundBril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52 · cited 1×
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo 37 .”
BackgroundAbdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., & Baek, S. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107176 · Cited by 51
Pooler, B. D., Wiens, C. N., McMillan, A., Artz, N. S., Schlein, A., Covarrubias, Y., Hooker, J., Schwimmer, J. B., Funk, L. M., Campos, G. M., et al. (2019) · Radiology · doi:10.1148/radiol.2018181134 · Cited by 37
Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S. (2020) · Journal of Hepatology · doi:10.1016/s0168-8278(20)30765-0 · Cited by 30 · cited 3×
“On the basis of cell culture studies, retatrutide is less potent than endogenous ligands of the human GCG and GLP-1 receptors (0.3 and 0.4 times as active, respectively) and is more potent at the human GIP receptor (by a factor of 8.9) 11 .”
BackgroundInfluentialMa, C., Shen, X., Qu, Y., & Du, Y. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2204 · Cited by 8
Self-citationHarrison, S., Tomah, S., Suschak, J., Roberts, S., Yang, J., He, L., Georges, B., Rodwell-Green, L., Brown, R., Harris, M. S., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00517-2 · Cited by 4
Cited by
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“A phase IIa trial of retatrutide, a triple agonist of the GIP, GLP-1 and glucagon receptors, demonstrated that ~20% weight loss was associated with a near-maximal reduction in liver fat, with a plateau beyond 20% weight loss 234 .”
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
Metadata
- Authors
- Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L.
- Affiliations
- Virginia Commonwealth University (US)
- Dartmouth College (US)
- Eli Lilly (United States) (US)
- Eli Lilly (Germany) (DE)
- Corresponding author
- Sanyal, Arun J.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-06-10
- Volume
- 30
- Issue
- 7
- Pages
- 2037-2048
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11271400
- OpenAlex
- W4399500327
- Cited by
- 315
- References
- 50
- Citations by year
- 2026: 152 · 2025: 137 · 2024: 26
- FWCI
- 95.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, non-alcoholic fatty liver disease, liver fat reduction, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, glucagon receptor, obesity, insulin sensitivity, lipid metabolism, weight loss, abdominal fat
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Double-Blind Method, Fatty Acids, Fatty Liver, Female, Humans, Liver, Male, Middle Aged, Obesity, Peptides, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.